XCath, a medical device company developing robotic technology for neuro-endovascular procedures, has secured $30 million in Series C funding to advance development and commercialization of its endovascular surgical robot. The round was co-led by Crescent Enterprises and Dr. Fred Moll, chairman of the company’s board of directors.
The new financing brings XCath’s total funding since its 2017 founding to $92 million. The company said the capital will support continued development of its robotic platform and efforts toward clinical telerobotic mechanical thrombectomy, a stroke treatment procedure that could potentially expand access to specialized neurovascular care.
The Houston-based startup is developing the Iris robotic system, which it says is designed for neurointerventional procedures involving the brain’s blood vessels. The company reported that in November 2025 the system was used in first-in-human procedures to treat patients with complex brain aneurysms. The procedures were performed by Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, with Dr. Anastasio Ameijeiras Sibauste serving as local principal investigator.
According to XCath, the procedures represented only the second time in history that a surgical robot had been used in an intracranial neurovascular intervention. The company said the Iris platform is currently the only endovascular robotic system in development to achieve intracranial navigation or neurointerventional treatment.
XCath also noted that the system has performed an intracranial neurovascular procedure involving robotic manipulation of three devices and has operated using standard monoplane imaging equipment, which could support broader adoption in clinical settings.
The company is currently operating from campuses in Houston, Texas and Pangyo, South Korea, and is focused on expanding access to advanced stroke and neurovascular care globally. XCath said its endovascular robotic system remains under development and has not yet been cleared for commercial distribution in any country.
KEY QUOTES
“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases. In 2025 the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”
Eduardo Fonseca, Chief Executive Officer of XCath
“Robotic surgery succeeds when innovation is paired with practical execution. XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”
Dr. Fred Moll, Chairman of the Board of Directors at XCath
“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs and engineers, clearly focused on addressing a significant global healthcare unmet need.”
Neeraj Agrawal, Board Member at XCath and Executive Director at Crescent Enterprises
“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems. With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics.”
Nicholas Drysdale, Chief Financial Officer of XCath
